| Autor: |
Tombak, A, Ucar, MA, Akdeniz, A, Tiftik, EN, Sahin, DG, Akay, OM, Yildirim, M, Nevruz, O, Kis, C, Gurkan, E, Solmaz, SM, Ozcan, MA, Yildirim, R, Berber, I, Erkurt, MA, Tuglular, TF, Tarkun, P, Yavasoglu, I, Dogu, MH, Sari, I, Merter, M, Ozcan, M, Yildizhan, E, Kaynar, L, Mehtap, O, Uysal, A, Sahin, F, Salim, O, Sungur, MA |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Popis: |
Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of >= 60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of = 5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
